Showing 2051-2060 of 6036 results for "".
- Zeiss and IDOC Partner to Bring Medical and Vision Care Products to Independent Optometrists Nationwidehttps://modernod.com/news/zeiss-and-idoc-partner-to-bring-medical-and-vision-care-products-to-independent-optometrists-nationwide/2476890/IDOC, Zeiss Vision Care US and Zeiss Medical Technology announced a 5-year agreement to bring Zeiss’ lab services, lens products and medical equipment to all 3,000+ IDOC independent optometrists across the United Stat
- EyeSouth Establishes Presence in Alabama Through Affiliation with Montgomery Eye Physicianshttps://modernod.com/news/eyesouth-establishes-presence-in-alabama-through-affiliation-with-montgomery-eye-physicians/2476711/EyeSouth Partners has announced that it has completed an affiliation with Montgomery Eye Physicians and Prescription Eyewear. The affiliation will be EyeSouth’s first in Alabama. Terms of the deal were not disclosed. EyeSouth is an eye care-focused management services organization.
- Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukoshttps://modernod.com/news/ripple-therapeutics-announces-evaluation-and-licensing-agreements-with-glaukos/2482502/Ripple Therapeutics announced a new evaluation and licensing agreement with Glaukos this week that aims to leverage Ripple’s patented technology platform to create sustained release implants of targeted therapeutics for both glaucoma and retinal diseases. Financial terms of the de
- Retina Community Mourns the Loss of Ramin Tadayoni, MD, PhDhttps://modernod.com/news/retina-community-mourns-the-loss-of-ramin-tadayoni-md-phd/2482240/Prof. Ramin Tadayoni, MD, PhD, a giant in the global retina community, passed away on Friday. A respected leader, investigator, mentor, and educator, Prof. Tadayoni was the head of the ophthalmology department at the Fondation Adolphe de Rothschild and the Lariboisière and Saint-
- Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCEDhttps://modernod.com/news/kala-pharmaceuticals-announces-fda-acceptance-of-ind-application-for-kpi-012-for-the-treatment-of-pced/2481312/Kala Pharmaceuticals announced that the FDA has accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome (MSC-S), initially in development for the treatment of persistent corneal epithelial de
- Luminopia Announces FDA Approval of Digital Therapeutic to Improve Vision in Children with Lazy Eyehttps://modernod.com/news/luminopia-announces-fda-approval-of-digital-therapeutic-to-improve-vision-in-children-with-lazy-eye/2480369/Luminopia announced that the FDA has granted de novo premarket approval for Luminopia One as a prescription therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss in children. Luminopia One is indicated for improvement in visual acuity in child
- American Vision Partners Notifies Patients of Cybersecurity Incidenthttps://modernod.com/news/american-vision-partners-notifies-patients-of-cybersecurity-incident/2482103/Medical Management Resource Group (MMRG), doing business as American Vision Partners, provided notice of a cybersecurity incident affecting information the company maintains in connection with performing services. American Vision Partners provides administrative services to ophthalmolog
- Glaukos Comments on the CMS 2022 Proposed Physician Fee Schedulehttps://modernod.com/news/glaukos-comments-on-the-cms-2022-proposed-physician-fee-schedule/2479412/Glaukos commented on the recently released Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule Proposed Rule. The Proposed Rule was released on July 13, 2021, and updates payment policies, payment rates and other provisions for services furnished un
- Medicare Plans to Phase in Changes for Office-Visit Paymentshttps://modernod.com/news/medicare-plans-to-phase-in-changes-for-office-visit-payments/2479706/The Centers for Medicare & Medicaid Services (CMS) said it will phase in changes to payments to physicians for office visits, proceeding over the objection of many medical groups with its overhaul of reimbursement for evaluation and management (E&M) services, according to a Medscape
- Glaukos Expands its Preserflo MicroShunt Relationship With Santen Via New License Agreementhttps://modernod.com/news/glaukos-expands-its-preserflo-microshunt-relationship-with-santen-via-new-license-agreement/2479228/Glaukos announced that it has entered into a new development and commercialization license agreement with Santen Pharmaceutical for the Preserflo MicroShunt (development code: DE-128), superseding the previous collaboration and distribution agreements between the two parties. Financial ter